Movement Alert｜Moderna Rises 5.06% in Regular Trading, Secures Up to $50 Million CEPI Grant for Ebola Vaccine Development

Market Focus06-04

On June 4, Moderna rose 5.06% in regular trading, trading at $48.04/share, with trading volume of $134 million. The rally was driven by the announcement of an expanded partnership with the Coalition for Epidemic Preparedness Innovations (CEPI).

Specifically, CEPI has committed up to $50 million in funding to support Moderna's Bundibugyo Ebola virus vaccine candidate through preclinical development and Phase 1 clinical trials. The grant will also fund parallel manufacturing activities during clinical evaluation and lay the groundwork for subsequent large-scale Phase 2/3 trials. This collaboration underscores Moderna's mRNA platform capabilities in addressing global public health threats beyond its core COVID-19 franchise.

Separately, Moderna recently disclosed plans to have its recommended COVID vaccine component supply for the upcoming season ready by mid-August, positioning the company well for the fall immunization campaign. The combination of new funding partnerships and operational readiness appears to have bolstered investor confidence in the company's diversified pipeline and revenue sustainability.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1163120710?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-04 01:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1163120710","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Moderna Rises 5.06% in Regular Trading, Secures Up to $50 Million CEPI Grant for Ebola Vaccine Development","media":"Market Focus","content":"<p><p>On June 4, Moderna rose 5.06% in regular trading, trading at $48.04/share, with trading volume of $134 million. The rally was driven by the announcement of an expanded partnership with the Coalition for Epidemic Preparedness Innovations (CEPI).</p><p>Specifically, CEPI has committed up to $50 million in funding to support Moderna's Bundibugyo Ebola virus vaccine candidate through preclinical development and Phase 1 clinical trials. The grant will also fund parallel manufacturing activities during clinical evaluation and lay the groundwork for subsequent large-scale Phase 2/3 trials. This collaboration underscores Moderna's mRNA platform capabilities in addressing global public health threats beyond its core COVID-19 franchise.</p><p>Separately, Moderna recently disclosed plans to have its recommended COVID vaccine component supply for the upcoming season ready by mid-August, positioning the company well for the fall immunization campaign. The combination of new funding partnerships and operational readiness appears to have bolstered investor confidence in the company's diversified pipeline and revenue sustainability.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Moderna Rises 5.06% in Regular Trading, Secures Up to $50 Million CEPI Grant for Ebola Vaccine Development</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Moderna Rises 5.06% in Regular Trading, Secures Up to $50 Million CEPI Grant for Ebola Vaccine Development\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-04 01:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 4, Moderna rose 5.06% in regular trading, trading at $48.04/share, with trading volume of $134 million. The rally was driven by the announcement of an expanded partnership with the Coalition for Epidemic Preparedness Innovations (CEPI).</p><p>Specifically, CEPI has committed up to $50 million in funding to support Moderna's Bundibugyo Ebola virus vaccine candidate through preclinical development and Phase 1 clinical trials. The grant will also fund parallel manufacturing activities during clinical evaluation and lay the groundwork for subsequent large-scale Phase 2/3 trials. This collaboration underscores Moderna's mRNA platform capabilities in addressing global public health threats beyond its core COVID-19 franchise.</p><p>Separately, Moderna recently disclosed plans to have its recommended COVID vaccine component supply for the upcoming season ready by mid-August, positioning the company well for the fall immunization campaign. The combination of new funding partnerships and operational readiness appears to have bolstered investor confidence in the company's diversified pipeline and revenue sustainability.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"","article_id":"1163120710","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1163120710","pubTimestamp":1780509349,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 4, Moderna rose 5.06% in regular trading, trading at $48.04/share, with trading volume of $134 million. The rally was driven by the announcement of an expanded partnership with the Coalition...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"动向提示|Moderna常规交易涨5.06%获高达5000万美元CEPI拨款用于埃博拉疫苗研发","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":1},"content_text":"On June 4, Moderna rose 5.06% in regular trading, trading at $48.04/share, with trading volume of $134 million. The rally was driven by the announcement of an expanded partnership with the Coalition for Epidemic Preparedness Innovations (CEPI).Specifically, CEPI has committed up to $50 million in funding to support Moderna's Bundibugyo Ebola virus vaccine candidate through preclinical development and Phase 1 clinical trials. The grant will also fund parallel manufacturing activities during clinical evaluation and lay the groundwork for subsequent large-scale Phase 2/3 trials. This collaboration underscores Moderna's mRNA platform capabilities in addressing global public health threats beyond its core COVID-19 franchise.Separately, Moderna recently disclosed plans to have its recommended COVID vaccine component supply for the upcoming season ready by mid-August, positioning the company well for the fall immunization campaign. The combination of new funding partnerships and operational readiness appears to have bolstered investor confidence in the company's diversified pipeline and revenue sustainability.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1163120710","isCrawlerRequest":true}